This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Healthcare & Biotech ETFs Digest GILD's Failure News: 5 Winners
by Sanghamitra Saha
Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.
Acorda (ACOR) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
During Acorda's (ACOR) upcoming Q1 earnings call, investor focus will be on the sales uptake of its newly-launched Parkinson's disease drug, Inbrija.
Can Vertex (VRTX) Withstand the Coronavirus Impact on Q1 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) first-quarter earnings call, investor focus will be on the sales uptake of its newly-launched CF drug, Trikafta.
Will Gilead (GILD) Beat Q1 Earnings Despite Coronavirus Mayhem?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance along with updates on experimental coronavirus treatment, when Gilead (GILD) reports first-quarter 2020 results.
Stock Market News for Apr 24, 2020
by Zacks Equity Research
U.S. stocks moved little in Thursday's session, due to lack of any solid market-moving news.
Are The Equity Markets Over Optimistic?
by Daniel Laboe
The global economy has been put into a medically induced coma, with the pandemic forcing economies around the world to pause
Ride Out the Coronavirus Mayhem With These ETF Areas
by Sweta Jaiswal, FRM
We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Healthcare ETFs Looks Strong Ahead of Q1 Earnings
by Sweta Killa
The healthcare sector has been on a tear driven by potential vaccines and treatments for COVID-19.
Biotech Stock Roundup: ALXN, MRNA Up on Coronavirus Treatment Updates, & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Biotech ETFs Gaining on Progress in Coronavirus Treatment
by Sweta Jaiswal, FRM
The race to introduce vaccine and treatment for coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.
Coronavirus Makes Biotech ETFs Red Hot
by Sweta Killa
The biotech space of the broader healthcare sector is currently the hottest of all segments buoyed by the COVID-19 pandemic.
The Zacks Analyst Blog Highlights: Alphabet, Gilead Sciences, Starbucks, Tesla and Intuit
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, Gilead Sciences, Starbucks, Tesla and Intuit
4 Top Sectors of Last Week & Their Winning ETFs
by Sanghamitra Saha
These sectors topped last week and beat the broader market in a sweeping move.
5 Best Sector ETFs Halfway Through April
by Sweta Killa
Given the positive developments, almost every corner of the equity world are experiencing a huge rally. Below, we have highlighted ETFs from five different segments that are leading the way in mid April.
Biotech ETF (BBH) Hits New 52-Week High
by Sweta Killa
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
Stock Market News for Apr 20, 2020
by Zacks Equity Research
U.S. stocks surged on Friday, thanks to investor optimism over a possible cure to the deadly coronavirus and President Donald Trump's plans to gradually reopen U.S. economy.
Biogen (BIIB) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Biogen's (BIIB) performance when it reports first-quarter results.
Gilead (GILD) in Focus: Stock Moves 9.7% Higher
by Zacks Equity Research
Gilead (GILD) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Gilead Increases Enrollment Target, Pharma Rally Continues
by Ritujay Ghosh
Substantial progress has been made over the past few weeks with pharmaceutical companies speeding up development of coronavirus vaccines.
5 Best Leveraged ETF Areas of Last Week
by Sanghamitra Saha
If investors can identify the trending investing area amid all the coronavirus chaos, they can easily take a leveraged position on that and beat the broader market.
Earnings Scorecard and Top Stock Reports for Alphabet, Gilead & Starbucks
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Gilead Sciences (GILD) and Starbucks (SBUX).
Markets Up on COVID-19 Treatment Data
by Mark Vickery
Remsdesivir, a daily infusion treatment from Gilead Sciences (GILD) that has so far shown positive results in a phase-3 study at the University of Chicago Medicine.
Futures Up on Coronavirus Treatment Data
by Zacks Equity Research
Futures Up on Coronavirus Treatment Data
Gilead's (GILD) Coronavirus Drug Shows Promise, Shares Gain
by Zacks Equity Research
Treatment with Gilead's (GILD) experimental antiviral, remdesivir, shows rapid recoveries in fever and respiratory symptoms in COVID-19 patients in a Chicago hospital.